Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina
- HIV/HCV coinfection liver disease pathogenesis
- HCV therapeutics
- HIV/HCV healthcare utilization
- Clinical trials of antiviral drugs
- HIV/HCV natural history and clinical outcomes
Dr Susanna Naggie is an Associate Professor of Medicine at Duke University School of Medicine. She holds a joint appointment in the Section of GI/Hepatology Research at the Duke Clinical Research Institute where she is involved in Phase I-III Clinical Trials. She staffs two HIV/HCV coinfection multidisciplinary clinics at Duke and the Durham VA. She serves as an inpatient attending physician on ID consults and general internal medicine at the Durham VA Medical Center.
- IAS–USA Viral Hepatitis Co-Chair
- HIV Integrated Learning Modules: Achieving Performance Improvement through Collaboration (VISION) Steering Committee
- Infectious Diseases Society of America (2008-present)
- American Association for the Study of Liver Diseases (2010-present)
- European Association for the Study of the Liver (2010-present)
- International AIDS Society (2010-present)
- AMA/WPC Physicians Mentor Recognition (2007)
- General Medicine Teaching Award, Duke General Medicine Wards (2006)
- Golden Apple Attending Teaching Award Nominee (2006)
- University of Maryland College Park, BS, Chemical Engineering (1998)
- Johns Hopkins University School of Medicine, MD, Medicine (2002)
- Duke University Medical Center, Resident, Internal Medicine (2005)
- Duke University Medical Center, Fellow, Infectious Diseases (2009)
- Duke University Clinical Research Training Program, MHS, Clinical Research (2010)
- Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2010;(In press).
- Rallon NI, Restrepo C, Naggie S, et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS. 2011;25:269-271.
- Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to Therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2010;51:1209-1216.
- Thompson AJ, Muir AJ, Sulkowski MS, et al. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology. 2010;52:2243-2244.
- Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother. 2010;65:2063-2069.
- Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181-1189.
- Naggie S, Frederick J, Pien BC, et al. Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA. Infection. 2010;38:297-300.
- Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23-F29.
- Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother. 2010;65:1094-1099.
- Naggie S, Hseih T, Reckleff J, Castellano J, Hicks CB. Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. Clin Infect Dis. 2009;49:1619-1620.